https://www.pharmaradar360.com/article/vivani-medical-announces-appointment-of-august-j-moretti-to-board-of-directors-a-2d214fdf66cad5b4Pharma Surgeen2026-06-26T11:30:00.000ZVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Bakerhttps://www.pharmaradar360.com/article/manushield-cleaner-d4dab93d8cc47949Pharma Surgeen2026-06-26T11:22:29.000ZΑνάκληση παρτίδας του προϊόντος MANUSHIELD CLEANERhttps://www.pharmaradar360.com/article/now-zinc-gluconate-50mg-250-tabs-93c4f17b9d93a07bPharma Surgeen2026-06-26T11:18:26.000ZΑπαγόρευση διάθεσης και διακίνησης του συμπληρώματος διατροφής NOW ZINC GLUCONATE 50MG, 250 TABShttps://www.pharmaradar360.com/article/lilly-s-jaypirca-pirtobrutinib-recommended-by-chmp-for-approval-in-the-european-ed46d54504400b6aPharma Surgeen2026-06-26T11:16:00.000ZLilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapyhttps://www.pharmaradar360.com/article/hiro-lab-tongkat-ali-400mg-hiro-lab-turkesterone-600mg-1c8da9c4681bb79cPharma Surgeen2026-06-26T11:11:38.000ZΑπαγόρευση διάθεσης και διακίνησης των συμπληρωμάτων διατροφής Hiro.Lab Tongkat Ali 400MG, Hiro.Lab Turkesterone 600mghttps://www.pharmaradar360.com/article/key-takeaways-from-a-chronicle-examination-of-empower-pharmacy-3f7bc426d7b1091cPharma Surgeen2026-06-26T11:08:31.000ZKey takeaways from a Chronicle examination of Empower Pharmacyhttps://www.pharmaradar360.com/article/we-spent-a-year-examining-empower-pharmacy-s-expansion-in-the-compounding-world-2c4a74ba264d1b69Pharma Surgeen2026-06-26T11:08:31.000ZWe spent a year examining Empower Pharmacy’s expansion in the compounding world. Here’s how we did it.https://www.pharmaradar360.com/article/omakase-world-market-is-the-bay-area-s-most-surprising-new-food-hall-31b68bc365e513a5Pharma Surgeen2026-06-26T11:03:07.000ZOmakase World Market is the Bay Area's most surprising new food hallhttps://www.pharmaradar360.com/article/fda-to-discuss-easing-restrictions-on-peptides-despite-safety-concerns-ba8fa9e1bcd94824Pharma Surgeen2026-06-26T11:02:00.000ZFDA to discuss easing restrictions on peptides despite safety concernshttps://www.pharmaradar360.com/article/axsome-starts-468-patient-adhd-trial-for-teens-4d97a5f680596e79Pharma Surgeen2026-06-26T11:00:00.000ZAxsome starts 468-patient ADHD trial for teenshttps://www.pharmaradar360.com/article/aethlon-medical-tracks-ebola-outbreak-readies-hemopurifier-talks-9f3bb3559a64882bPharma Surgeen2026-06-26T11:00:00.000ZAethlon Medical tracks Ebola outbreak, readies Hemopurifier talkshttps://www.pharmaradar360.com/article/from-vaccines-to-therapeutics-how-biotech-is-addressing-the-ebola-outbreak-a75589f8f3267be3Pharma Surgeen2026-06-26T11:00:00.000ZFrom Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreakhttps://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-21e80aa813c48412Pharma Surgeen2026-06-26T10:32:27.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to January to March 2026https://www.pharmaradar360.com/article/mexiletine-pr-564e51f22fbdac57Pharma Surgeen2026-06-26T10:21:39.000ZMexiletine PRhttps://www.pharmaradar360.com/article/hepatitis-b-antenatal-screening-and-selective-neonatal-immunisation-pathway-d8b93786f729959cPharma Surgeen2026-06-26T10:11:56.000ZHepatitis B: antenatal screening and selective neonatal immunisation pathwayhttps://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-20a088b198fbcb50Pharma Surgeen2026-06-26T10:06:50.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/uk-malaria-expert-advisory-group-ukmeag-6b3d8243950c8703Pharma Surgeen2026-06-26T10:02:56.000ZUK Malaria Expert Advisory Group (UKMEAG)https://www.pharmaradar360.com/article/kazde-1-euro-zainwestowane-w-nowe-leki-przynosi-europie-5-67-euro-zwrotu-a686d6d0c71a0289Pharma Surgeen2026-06-26T09:49:10.000ZKażde 1 euro zainwestowane w nowe leki przynosi Europie 5,67 euro zwrotu.https://www.pharmaradar360.com/article/san-diego-biopharma-begins-first-in-human-dosing-of-obesity-drug-as-phase-3-cata-892ffe88dada61d6Pharma Surgeen2026-06-26T09:45:00.000ZSan Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approachhttps://www.pharmaradar360.com/article/intrathecal-antibody-test-request-form-ad4dcac995d99f1dPharma Surgeen2026-06-26T09:44:26.000ZIntrathecal antibody test request formhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-consun-pharmaceutical-group-ltd-hkex-1681-10dd56e132a422dbPharma Surgeen2026-06-26T09:44:13.000ZEnterprise value to EBIT forward of Consun Pharmaceutical Group Ltd. – HKEX:1681https://www.pharmaradar360.com/article/polyomavirus-jc-investigation-request-form-e13-5572d7f1731b0921Pharma Surgeen2026-06-26T09:40:57.000ZPolyomavirus JC investigation request form E13https://www.pharmaradar360.com/article/us-biotech-index-hits-record-high-danske-bank-cites-several-drivers-4077e21bef5cc833Pharma Surgeen2026-06-26T09:40:00.000ZUS biotech index hits record high, Danske Bank cites several drivershttps://www.pharmaradar360.com/article/price-to-book-forward-of-dizal-jiangsu-pharmaceutical-co-ltd-class-a-sse-688192-45cb49674c0d409fPharma Surgeen2026-06-26T09:37:52.000ZPrice to book forward of Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A – SSE:688192https://www.pharmaradar360.com/article/parvovirus-b19-referral-form-8dc7a59f7518c10aPharma Surgeen2026-06-26T09:37:08.000ZParvovirus B19 referral formhttps://www.pharmaradar360.com/article/varicella-zoster-virus-referral-form-87218879c2490674Pharma Surgeen2026-06-26T09:32:34.000ZVaricella zoster virus referral formhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-shandong-xinhua-pharmaceutical-company-limit-5e0bf2c3a3a6cab4Pharma Surgeen2026-06-26T09:31:13.000ZEnterprise value to EBIT forward of Shandong Xinhua Pharmaceutical Company Limited Class H – LSX:A0M4YVhttps://www.pharmaradar360.com/article/hhv-6-and-hhv-7-referral-form-a9e04d646937cbb7Pharma Surgeen2026-06-26T09:26:29.000ZHHV-6 and HHV-7 referral formhttps://www.pharmaradar360.com/article/cnx-and-legacy-set-july-us-relaunch-for-ethyol-ebe5303f1be89f14Pharma Surgeen2026-06-26T09:19:50.000ZCNX and Legacy set July US relaunch for Ethyolhttps://www.pharmaradar360.com/article/otsuka-posts-positive-phase-iiib-data-for-novel-adhd-therapy-822dbafb438e1266Pharma Surgeen2026-06-26T09:11:51.000ZOtsuka posts positive Phase IIIb data for novel ADHD therapyhttps://www.pharmaradar360.com/article/how-ibio-aims-to-stand-out-in-obesity-by-targeting-both-sides-of-the-equation-fo-0be528ca5f6669fbPharma Surgeen2026-06-26T09:00:14.000ZHow iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discoveryhttps://www.pharmaradar360.com/article/disponibilite-amelioree-du-zypadhera-poudre-et-solvant-pour-suspension-injectabl-b3a54536fec61316Pharma Surgeen2026-06-26T08:53:52.000ZDisponibilité améliorée du Zypadhera (poudre et solvant pour suspension injectable à libération prolongée) : assouplissement et recommandations adaptées pour les médecins (spécialistes), les pharmaciens (hospitaliers) et les patientshttps://www.pharmaradar360.com/article/debt-to-equity-ratio-of-gin-hwa-biotech-inc-tpex-7806-01f378f4e1b93d46Pharma Surgeen2026-06-26T08:53:50.000ZDebt to equity ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/pharmaceutical-technology-fb92345e3e5c13daPharma Surgeen2026-06-26T08:53:38.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/explosion-and-fire-at-pharmaceutical-facility-in-new-york-state-0516ee6382f69c90Pharma Surgeen2026-06-26T08:48:16.000ZExplosion and fire at pharmaceutical facility in New York Statehttps://www.pharmaradar360.com/article/long-term-debt-to-total-assets-ratio-of-gin-hwa-biotech-inc-tpex-7806-c7ca9b20a6acfc5fPharma Surgeen2026-06-26T08:44:04.000ZLong term debt to total assets ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/enterprise-value-of-gin-hwa-biotech-inc-tpex-7806-a8afe7c5336ff10fPharma Surgeen2026-06-26T08:41:49.000ZEnterprise value of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/debt-to-assets-ratio-of-gin-hwa-biotech-inc-tpex-7806-967f7174ee40d795Pharma Surgeen2026-06-26T08:40:53.000ZDebt to assets ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/krystal-biotech-krys-rallies-on-pipeline-optimism-is-the-stock-already-pricey-fee4ba808a83171fPharma Surgeen2026-06-26T08:39:03.000ZKrystal Biotech (KRYS) Rallies On Pipeline Optimism, Is The Stock Already Pricey?https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-gin-hwa-biotech-inc-tpex-7806-e536e0169386cdbfPharma Surgeen2026-06-26T08:37:48.000ZEnterprise value to EBIT forward of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-gin-hwa-biotech-inc-tpex-7806-5282c66628bef04aPharma Surgeen2026-06-26T08:37:06.000ZEnterprise value to revenue forward of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/price-to-book-forward-of-pharmagreen-biotech-inc-otc-phbi-877eb5b0e73534adPharma Surgeen2026-06-26T08:37:02.000ZPrice to book forward of Pharmagreen Biotech Inc. – OTC:PHBIhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-ratio-of-gin-hwa-biotech-inc-tpex-7806-5cf1854633d84a95Pharma Surgeen2026-06-26T08:36:52.000ZEnterprise value to EBITDA ratio of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/operating-margin-of-gin-hwa-biotech-inc-tpex-7806-cfd5502829f86eebPharma Surgeen2026-06-26T08:36:17.000ZOperating margin % of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/net-margin-of-gin-hwa-biotech-inc-tpex-7806-64015955cdc56150Pharma Surgeen2026-06-26T08:35:33.000ZNet margin % of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/uk-biotech-thalia-therapeutics-raises-3-1-million-and-acquires-sanmirna-therapeu-c97cd65a592b2ee4Pharma Surgeen2026-06-26T08:34:20.000ZUK BioTech Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeuticshttps://www.pharmaradar360.com/article/internal-eu-document-biotech-act-has-only-limited-impact-e7327a15d15f6f0fPharma Surgeen2026-06-26T08:31:47.000ZInternal EU document: Biotech Act has only limited impacthttps://www.pharmaradar360.com/article/new-aspe-report-finds-u-s-revenue-fuels-disproportionate-share-of-pharmaceutical-2377f20dbad85fc4Pharma Surgeen2026-06-26T08:31:00.000ZNew ASPE Report Finds U.S. Revenue Fuels Disproportionate Share of Pharmaceutical R&D Incentiveshttps://www.pharmaradar360.com/article/clostridioides-difficile-ribotyping-network-cdrn-report-cd445f04a8fc7f7fPharma Surgeen2026-06-26T08:30:00.000ZClostridioides difficile ribotyping network (CDRN) reporthttps://www.pharmaradar360.com/article/1-2026-811dc4dddb802ca1Pharma Surgeen2026-06-26T08:25:50.000ZΤιμολόγηση Νέων Φαρμακευτικών Προϊόντων_Νέα 1ου Τριμήνου 2026_Ανατιμολόγηση προϊόντων αναφοράς λόγω λήξης της προστασίας δεδομένων τους_Εξέταση αιτημάτων αναπροσαρμογής τιμής μη αποζημιούμενων σκευασμάτωνhttps://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-3b5125a476d37863Pharma Surgeen2026-06-26T08:23:33.000ZDHSC: business appointment rules advicehttps://www.pharmaradar360.com/article/dhsc-business-appointment-rules-advice-january-to-march-2026-9c825b6c03b30e94Pharma Surgeen2026-06-26T08:23:31.000ZDHSC: business appointment rules advice, January to March 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-28-june-2026-d61cebbdb2add2dePharma Surgeen2026-06-26T08:13:06.000ZWeekly all-cause mortality surveillance: week ending 28 June 2026https://www.pharmaradar360.com/article/lilly-launches-the-memory-radio-station-across-europe-inviting-the-public-to-vis-a0c91c981e0a2b2ePharma Surgeen2026-06-26T08:00:00.000ZLilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories through GenAIhttps://www.pharmaradar360.com/article/expired-gear-missing-records-2-mumbai-thane-blood-centres-shut-over-safety-lapse-4c338748db5d7bd7Pharma Surgeen2026-06-26T07:41:03.000ZExpired gear, missing records: 2 Mumbai, Thane blood centres shut over safety lapseshttps://www.pharmaradar360.com/article/proqr-validates-rna-editing-platform-and-raises-59-2m-fb73a6cbf3661ba9Pharma Surgeen2026-06-26T07:37:24.000ZProQR validates RNA editing platform and raises $59.2mhttps://www.pharmaradar360.com/article/assenagon-asset-management-s-a-decreases-stock-holdings-in-teva-pharmaceutical-i-340ad7b850fadc3aPharma Surgeen2026-06-26T07:17:58.000ZAssenagon Asset Management S.A. Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/what-does-briacell-s-latest-offering-mean-for-shareholders-0945e6fa4f984948Pharma Surgeen2026-06-26T06:55:58.000ZWhat Does BriaCell's Latest Offering Mean for Shareholdershttps://www.pharmaradar360.com/article/gcp-breakdown-at-king-s-college-hospital-just-clouded-the-most-promising-parkins-5284224154e6aa79Pharma Surgeen2026-06-26T06:53:06.000ZGCP Breakdown at King’s College Hospital Just Clouded the Most Promising Parkinson’s Trial in Yearshttps://www.pharmaradar360.com/article/unapproved-retatrutide-use-challenges-clinicians-a54228fb90667cfdPharma Surgeen2026-06-26T06:42:33.000ZUnapproved Retatrutide Use Challenges Clinicianshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-teva-pharmaceutical-industries-limited-sp-18729f331f01cd3dPharma Surgeen2026-06-26T06:35:22.000ZEnterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEVhttps://www.pharmaradar360.com/article/helus-shares-experience-studying-adjunctive-psychedelic-for-major-depressive-dis-4b3d93d40f3cc793Pharma Surgeen2026-06-26T06:31:40.000ZHelus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorderhttps://www.pharmaradar360.com/article/rtw-biotech-invests-1-4-million-in-lycia-series-d-financing-3354a90a154b3c54Pharma Surgeen2026-06-26T06:30:00.000ZRTW Biotech Invests $1.4 Million In Lycia Series D Financinghttps://www.pharmaradar360.com/article/3-clinical-stage-biotech-stocks-worth-watching-in-parkinson-s-research-ddf5ae08cf0d24b4Pharma Surgeen2026-06-26T06:22:08.000Z3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Researchhttps://www.pharmaradar360.com/article/korea-s-chip-fund-makes-first-biotech-bet-backing-ligachem-with-323-million-719fc6787bbc7329Pharma Surgeen2026-06-26T06:19:52.000ZKorea's chip fund makes first biotech bet, backing LigaChem with $323 millionhttps://www.pharmaradar360.com/article/korea-s-chip-fund-makes-first-biotech-bet-backing-ligachem-with-323-million-202b0cd2cf33f5afPharma Surgeen2026-06-26T05:50:13.000ZKorea's chip fund makes first biotech bet, backing LigaChem with $323 millionhttps://www.pharmaradar360.com/article/first-aid-biotech-act-deal-by-christmas-95157e9e88af4606Pharma Surgeen2026-06-26T05:48:01.000ZFIRST AID: Biotech Act deal by Christmas?https://www.pharmaradar360.com/article/lupin-gets-tentative-us-fda-approval-for-generic-prostate-cancer-drug-9fc4898b6ced2be7Pharma Surgeen2026-06-26T05:29:01.000ZLupin gets tentative US FDA approval for generic prostate cancer drughttps://www.pharmaradar360.com/article/from-data-to-decisions-how-ipsen-turns-medical-data-into-action-for-patients-ea0233d867d2b2abPharma Surgeen2026-06-26T05:01:55.000ZFrom data to decisions: how Ipsen turns medical data into action for patientshttps://www.pharmaradar360.com/article/why-is-sanofi-s-tolebrutinib-facing-a-regulatory-split-941a9c08b59ee378Pharma Surgeen2026-06-26T04:38:53.000ZWhy is Sanofi's Tolebrutinib Facing a Regulatory Splithttps://www.pharmaradar360.com/article/what-do-moonlake-s-latest-week-40-hs-results-really-mean-for-investors-9f702ce2a4a5c8ffPharma Surgeen2026-06-26T03:14:47.000ZWhat Do MoonLake's Latest Week 40 HS Results Really Mean for Investorshttps://www.pharmaradar360.com/article/how-glp-1-demand-is-reshaping-pharma-manufacturing-strategy-449d3c541f79107aPharma Surgeen2026-06-26T01:58:08.000ZHow GLP-1 Demand Is Reshaping Pharma Manufacturing Strategyhttps://www.pharmaradar360.com/article/drug-maker-sues-to-halt-implementation-of-arkansas-new-pharmaceutical-distributi-3bc547afe7c747d7Pharma Surgeen2026-06-26T01:30:00.000ZDrug maker sues to halt implementation of Arkansas' new pharmaceutical distribution lawhttps://www.pharmaradar360.com/article/recce-pharmaceuticals-rce-investor-presentation-summary-0037e81161ff9200Pharma Surgeen2026-06-26T01:28:31.000ZRecce Pharmaceuticals (RCE) Investor presentation Summaryhttps://www.pharmaradar360.com/article/recce-raises-a-4m-as-it-advances-anti-infective-trials-and-commercial-licensing-05a6e7bac0e1db4ePharma Surgeen2026-06-26T01:12:16.000ZRecce raises A$4M as it advances anti-infective trials and commercial licensing plans; another $4M to come in SPPhttps://www.pharmaradar360.com/article/hong-kong-biotech-delegation-makes-strong-us-showing-at-bio-2026-b7b6971a50a5ae48Pharma Surgeen2026-06-26T01:10:08.000ZHong Kong biotech delegation makes strong US showing at BIO 2026https://www.pharmaradar360.com/article/dailypharmkorea-239d9f58bc2463c6Pharma Surgeen2026-06-26T00:50:24.000Z데일리팜코리아, 데일리팜 영문뉴스, dailypharmkoreahttps://www.pharmaradar360.com/article/santen-obtains-marketing-approval-in-the-philippines-for-stn1012700-ryjusea-0-25-c50cd231bb348a46Pharma Surgeen2026-06-26T00:00:00.000ZSanten Obtains Marketing Approval in the Philippines for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia — First Approval in Santen’s Asia Business Regionhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-40cf7cf002d36d75Pharma Surgeen2026-06-26T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-44c0532613516e29Pharma Surgeen2026-06-26T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-dbe485666a40899fPharma Surgeen2026-06-26T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-4230d64e81acd0ecPharma Surgeen2026-06-26T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-37e0607ce5410c12Pharma Surgeen2026-06-26T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-88e664c7644b0c4cPharma Surgeen2026-06-26T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-d9c52d839cb9bf84Pharma Surgeen2026-06-26T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-3e71d955558b752fPharma Surgeen2026-06-26T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-9534a207a0ad4f40Pharma Surgeen2026-06-26T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5e515ca7a216fb62Pharma Surgeen2026-06-26T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-0de1dfd7d06b05f0Pharma Surgeen2026-06-26T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-1e658f374adfa84bPharma Surgeen2026-06-26T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-001eb51041da80d6Pharma Surgeen2026-06-26T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-bf13e4cf8344a7d3Pharma Surgeen2026-06-26T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pro-1e4392a0904f6fb2Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Request Proposed Project: Request To Publish the 30-Day Notices in the Federal Register To Solicit Public Comment on Information Collection for the Continued Approval and Updates for the Protection and Advocacy for Individuals Wihttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-d412273cbac0868fPharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Submission for Office of Management and Budget Review (OMB); Comment Requesthttps://www.pharmaradar360.com/article/proposed-information-collection-activity-tanf-contingency-fund-application-8e6717d5e53dca83Pharma Surgeen2026-06-26T00:00:00.000ZProposed Information Collection Activity; TANF Contingency Fund Applicationhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-62a3870eb31c6b22Pharma Surgeen2026-06-26T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/determination-that-prednisolone-tablet-5-milligrams-was-not-withdrawn-from-sale-5cbb9930f4b8110cPharma Surgeen2026-06-26T00:00:00.000ZDetermination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-0ce06407fb5fbc40Pharma Surgeen2026-06-26T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/determination-that-rectiv-nitroglycerin-ointment-0-4-was-not-withdrawn-from-sale-78aacdef6bdfd448Pharma Surgeen2026-06-26T00:00:00.000ZDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/unaccompanied-children-program-foundational-rule-sponsor-assessment-update-to-in-79e62fa99dd15119Pharma Surgeen2026-06-26T00:00:00.000ZUnaccompanied Children Program Foundational Rule; Sponsor Assessment Update To Include Proof of Identity, Background Check, Placement, and Income Verification Standardshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-ac6642209c0f46e5Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-50-51dfcd447654846fPharma Surgeen2026-06-26T00:00:00.000ZList of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Periodhttps://www.pharmaradar360.com/article/drugs-for-human-use-drug-efficacy-study-implementation-estrogen-androgen-fixed-c-c14fdf1b589c4f6fPharma Surgeen2026-06-26T00:00:00.000ZDrugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661https://www.pharmaradar360.com/article/medicare-program-cy-2027-changes-to-the-end-stage-renal-disease-esrd-prospective-46be29354f50792dPharma Surgeen2026-06-26T00:00:00.000ZMedicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Programhttps://www.pharmaradar360.com/article/revocation-of-three-authorizations-of-emergency-use-of-in-vitro-diagnostic-devic-c8b1e6f1317763d8Pharma Surgeen2026-06-26T00:00:00.000ZRevocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availabilityhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-deed70298e92f6c8Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep Systemhttps://www.pharmaradar360.com/article/medical-devices-neurological-devices-classification-of-the-external-lower-extrem-e26723df872266e0Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs Syndromehttps://www.pharmaradar360.com/article/medical-devices-general-and-plastic-surgery-devices-classification-of-the-breast-4889dc353305df41Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General and Plastic Surgery Devices; Classification of the Breast Implant Suction Retrieval Systemhttps://www.pharmaradar360.com/article/medical-devices-immunology-and-microbiology-devices-classification-of-the-sars-c-f3473c1857637408Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Immunology and Microbiology Devices; Classification of the SARS-CoV-2 Serology Testhttps://www.pharmaradar360.com/article/medical-devices-neurological-devices-classification-of-the-computerized-behavior-2bc12ac245122e6ePharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptomshttps://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-toxicology-devices-classification-of-the-60e5ee91ce323bfbPharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsiahttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-418ff1471f13e3d9Pharma Surgeen2026-06-26T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectanthttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-tim-ee7ed34151674cf3Pharma Surgeen2026-06-26T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Productshttps://www.pharmaradar360.com/article/solicitation-for-public-comments-on-the-development-of-an-independent-accreditat-093f9298ad9301ffPharma Surgeen2026-06-26T00:00:00.000ZSolicitation for Public Comments on the Development of an Independent Accreditation System for Certified Community Behavioral Health Clinic Expansion (CCBHC-E) Grant Recipientshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-1808010f787210ebPharma Surgeen2026-06-26T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/bacterial-infection-and-sepsis-associated-inflammation-mechanistic-insights-and-6d9e9026bb04e2c6Pharma Surgeen2026-06-26T00:00:00.000ZBacterial infection and sepsis-associated inflammation: Mechanistic insights and emerging clinical perspectiveshttps://www.pharmaradar360.com/article/mesenchymal-stem-cells-and-their-exosomes-in-cardiac-repair-advances-and-future-dc429e11c243a8e3Pharma Surgeen2026-06-26T00:00:00.000ZMesenchymal Stem Cells and Their Exosomes in Cardiac Repair: Advances and Future Directionshttps://www.pharmaradar360.com/article/clinical-profile-and-etiological-spectrum-of-scleritis-in-a-tertiary-care-centre-2165c3f502b38ce4Pharma Surgeen2026-06-26T00:00:00.000ZClinical Profile and Etiological Spectrum of Scleritis in a Tertiary Care Centrehttps://www.pharmaradar360.com/article/management-0f-fingertip-amputations-contemporary-surgical-options-235e8dac5248f895Pharma Surgeen2026-06-26T00:00:00.000ZManagement 0f Fingertip Amputations: Contemporary Surgical Optionshttps://www.pharmaradar360.com/article/beyond-skills-reimagining-clinical-education-for-a-transformative-future-2896b8b071127ac8Pharma Surgeen2026-06-26T00:00:00.000ZBeyond skills: Reimagining clinical education for a transformative futurehttps://www.pharmaradar360.com/article/literature-based-peer-support-to-enhance-self-acceptance-among-university-studen-3800d64fae6bd80cPharma Surgeen2026-06-26T00:00:00.000ZLiterature-Based Peer Support to Enhance Self-Acceptance Among University Studentshttps://www.pharmaradar360.com/article/digital-diseases-cb1a91384ca21b43Pharma Surgeen2026-06-26T00:00:00.000ZDigital Diseaseshttps://www.pharmaradar360.com/article/the-evolution-of-nerve-sparing-radical-prostatectomy-mechanisms-of-injury-econom-d5f1f5c8878159c8Pharma Surgeen2026-06-26T00:00:00.000ZThe Evolution of Nerve-Sparing Radical Prostatectomy: Mechanisms of Injury, Economic Impact, and the Potential Value of Intraoperative Nerve Visualizationhttps://www.pharmaradar360.com/article/time-dependent-association-of-thoracic-anthropometric-parameters-with-survival-a-07810224c2bf3104Pharma Surgeen2026-06-26T00:00:00.000ZTime-Dependent Association of Thoracic Anthropometric Parameters with Survival After In-Hospital Cardiac Arrest: A Retrospective Single-Center Observational Studyhttps://www.pharmaradar360.com/article/high-intensity-interval-training-on-cardiorespiratory-fitness-cognitive-function-f652ee812b48c75bPharma Surgeen2026-06-26T00:00:00.000ZHigh-Intensity Interval Training on Cardiorespiratory Fitness, Cognitive Function, and Functional Capacity in Adults with Stroke: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/prevalence-and-risk-factors-of-hypernatremic-dehydration-in-exclusively-breastfe-63ebaca6121d0010Pharma Surgeen2026-06-26T00:00:00.000ZPrevalence and Risk Factors of Hypernatremic Dehydration in Exclusively Breastfed Neonates: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/from-pandemic-innovation-to-platform-diversification-a-systematic-review-of-clin-fe6a7b851ef872eePharma Surgeen2026-06-26T00:00:00.000ZFrom Pandemic Innovation to Platform Diversification: A Systematic Review of Clinical and Preclinical Development of Non–SARS-CoV-2 mRNA Vaccineshttps://www.pharmaradar360.com/article/a-conceptual-clinical-reasoning-framework-for-early-syndromic-recognition-in-den-f763499f1a985b11Pharma Surgeen2026-06-26T00:00:00.000ZA conceptual clinical reasoning framework for early syndromic recognition in dental practicehttps://www.pharmaradar360.com/article/efficacy-and-predictors-of-cognitive-stimulation-therapy-combined-with-pharmacot-6180b954119c4d81Pharma Surgeen2026-06-26T00:00:00.000ZEfficacy and predictors of cognitive stimulation therapy combined with pharmacotherapy for mild-to-moderate Alzheimer’s disease: a randomized controlled trialhttps://www.pharmaradar360.com/article/editorial-advances-in-biomarkers-and-drug-targets-harnessing-traditional-and-ai-e31089ef5d055e10Pharma Surgeen2026-06-26T00:00:00.000ZEditorial: Advances in biomarkers and drug targets: harnessing traditional and AI approaches for novel therapeutic mechanismshttps://www.pharmaradar360.com/article/a-scoping-review-of-influenza-rdrp-targeting-inhibitors-mechanisms-clinical-tran-c1a19aefb63d195cPharma Surgeen2026-06-26T00:00:00.000ZA scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challengeshttps://www.pharmaradar360.com/article/early-prediction-of-late-pregnancy-hypertriglyceridemia-in-women-with-gestationa-5f48196cadf66466Pharma Surgeen2026-06-26T00:00:00.000ZEarly prediction of late-pregnancy hypertriglyceridemia in women with gestational diabetes: development and internal validation of a clinical risk modelhttps://www.pharmaradar360.com/article/advanced-hybrid-closed-loop-therapy-in-an-older-adult-with-55-year-type-1-diabet-14be449ab937eee2Pharma Surgeen2026-06-26T00:00:00.000ZAdvanced hybrid closed-loop therapy in an older adult with 55-year type 1 diabetes: a CARE-based case reporthttps://www.pharmaradar360.com/article/mindfulness-improves-stress-and-psycho-social-morbidities-of-cancer-patients-a-c-1b07df407c18522cPharma Surgeen2026-06-26T00:00:00.000ZMindfulness improves stress and psycho-social morbidities of cancer patients: a clinical trial using community group-therapy in the Indian contexthttps://www.pharmaradar360.com/article/analyzing-the-impact-of-post-covid-19-dynamics-on-coir-production-in-theni-distr-eacad6065e62029aPharma Surgeen2026-06-26T00:00:00.000ZAnalyzing The Impact Of Post-Covid-19 Dynamics On Coir Production In Theni Districthttps://www.pharmaradar360.com/article/optimization-development-and-evaluation-of-buccal-patch-loaded-sitagliptin-using-59d297b2ca9fb101Pharma Surgeen2026-06-26T00:00:00.000ZOptimization, Development and Evaluation of Buccal patch loaded Sitagliptin using natural polymershttps://www.pharmaradar360.com/article/clinical-efficacy-of-inosine-pranobex-in-combination-therapy-of-infectious-disea-592f996496b96957Pharma Surgeen2026-06-26T00:00:00.000ZClinical efficacy of inosine pranobex in combination therapy of infectious diseaseshttps://www.pharmaradar360.com/article/the-effect-of-sebia-s-cze-ifcc-converted-results-on-carbohydrate-deficient-trans-046c76ab63c9f880Pharma Surgeen2026-06-26T00:00:00.000ZThe effect of Sebia’s CZE IFCC-converted results on carbohydrate-deficient transferrin (CDT) interpretation in driver’s license assessmentshttps://www.pharmaradar360.com/article/monostotic-chronic-nonbacterial-osteomyelitis-chronic-recurrent-multifocal-osteo-5cd09a887570ef0aPharma Surgeen2026-06-26T00:00:00.000ZMonostotic chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis of clavicle mimicking malignant bone tumor: A case report and review of literaturehttps://www.pharmaradar360.com/article/extrapulmonary-tuberculosis-presenting-with-proximal-esophageal-fistula-and-abdo-b9ebfac5f3861094Pharma Surgeen2026-06-26T00:00:00.000ZExtrapulmonary tuberculosis presenting with proximal esophageal fistula and abdominal lymphadenopathy in a young man: A case reporthttps://www.pharmaradar360.com/article/trends-patterns-and-demographic-dynamics-of-drug-resistance-in-i-mycobacterium-t-5c21e84efa528da6Pharma Surgeen2026-06-26T00:00:00.000ZTrends, Patterns, and Demographic Dynamics of Drug Resistance in <i>Mycobacterium tuberculosis</i> and Nontuberculous: A Multi-Year Analysis at the National Tuberculosis Reference Laboratoryhttps://www.pharmaradar360.com/article/unlocking-the-scar-ultrasound-guided-hydrodissection-for-post-surgical-radial-ne-fa4fc2ebaf16d652Pharma Surgeen2026-06-26T00:00:00.000ZUnlocking the scar: ultrasound-guided hydrodissection for post-surgical radial nerve entrapment following clinical plateauhttps://www.pharmaradar360.com/article/commentary-on-impact-of-computer-aided-detection-on-endoscopist-s-gaze-shift-dis-5396377f8419f5b7Pharma Surgeen2026-06-26T00:00:00.000ZCommentary on “Impact of Computer‐Aided Detection on Endoscopist's Gaze‐Shift Distance During Colonoscopy: A Randomized Controlled Trial”https://www.pharmaradar360.com/article/the-impact-of-everyday-acoustic-environments-on-chronic-pain-mechanisms-in-fibro-d5ff88d1c2dec80aPharma Surgeen2026-06-26T00:00:00.000ZThe impact of everyday acoustic environments on chronic pain mechanisms in fibromyalgia: a randomized, triple-blind, placebo-controlled 4 × 4 crossover trialhttps://www.pharmaradar360.com/article/cui-curate-a-graphrag-based-framework-for-automated-clinical-concept-curation-fo-a2776017ae620193Pharma Surgeen2026-06-26T00:00:00.000ZCUI-Curate: a GraphRAG-based framework for automated clinical concept curation for NLP applicationshttps://www.pharmaradar360.com/article/dropless-after-cataract-surgery-dacs-concepts-evidence-and-clinical-potential-cc835707e4db0c8cPharma Surgeen2026-06-26T00:00:00.000ZDropless after cataract surgery (DACS): concepts, evidence and clinical potentialhttps://www.pharmaradar360.com/article/maternal-and-congenital-syphilis-in-fiji-2019-2022-a-secondary-analysis-of-clini-b25b07826858e3bfPharma Surgeen2026-06-26T00:00:00.000ZMaternal and congenital syphilis in Fiji 2019-2022: a secondary analysis of clinical trial datahttps://www.pharmaradar360.com/article/investigating-the-impact-of-calcium-channel-blockers-on-the-pharmacokinetics-of-b726471d3ad278e5Pharma Surgeen2026-06-26T00:00:00.000ZInvestigating the Impact of Calcium Channel Blockers on the Pharmacokinetics of Lapatinib: Possible Role of Cytochrome P450 Enzymes and P-glycoprotein Efflux Transportershttps://www.pharmaradar360.com/article/prevention-of-acute-enteritis-by-zno-nanoparticles-green-synthesized-using-leonu-7133101af38ad05aPharma Surgeen2026-06-26T00:00:00.000ZPrevention of Acute Enteritis by ZnO Nanoparticles Green-Synthesized using Leonurus japonicus Leaf Extracthttps://www.pharmaradar360.com/article/development-of-a-clinical-decision-support-system-for-exercise-prescription-amon-13b4b6af3c0ede25Pharma Surgeen2026-06-26T00:00:00.000ZDevelopment of a clinical decision support system for exercise prescription among cancer survivors: a modified Delphi studyhttps://www.pharmaradar360.com/article/dengue-and-natural-products-unveiling-nature-s-potential-in-antiviral-drug-disco-6a80819ab90ce492Pharma Surgeen2026-06-26T00:00:00.000ZDengue and natural products: unveiling nature’s potential in antiviral drug discoveryhttps://www.pharmaradar360.com/article/long-term-analysis-of-fibrosis-in-neovascular-age-related-macular-degeneration-a-07fa3bf7193a0eebPharma Surgeen2026-06-26T00:00:00.000ZLong-term analysis of fibrosis in neovascular age-related macular degeneration: A 7-year follow-uphttps://www.pharmaradar360.com/article/clinical-utility-of-18f-fet-pet-imaging-in-pediatric-brain-tumors-a-case-series-bdd848e99490ed6fPharma Surgeen2026-06-26T00:00:00.000ZClinical utility of [18F]-FET PET Imaging in pediatric brain tumors: a case serieshttps://www.pharmaradar360.com/article/secondary-peritoneal-leiomyomatosis-after-uterine-leiomyoma-intervention-multi-i-28f89c5b52626f30Pharma Surgeen2026-06-26T00:00:00.000ZSecondary peritoneal leiomyomatosis after uterine leiomyoma intervention: multi-institutional clinical and radiologic experiencehttps://www.pharmaradar360.com/article/what-is-the-risk-of-hcc-in-hypervascular-li-rads-3-observations-without-ancillar-fa3e16eb2efc9737Pharma Surgeen2026-06-26T00:00:00.000ZWhat is the risk of HCC in hypervascular LI-RADS 3 observations without ancillary features in routine clinical practice?https://www.pharmaradar360.com/article/a-ban-won-t-stop-abortion-pill-access-telehealth-providers-say-118580ca83bf5810Pharma Surgeen2026-06-25T23:00:04.000ZA ban won't stop abortion pill access, telehealth providers sayhttps://www.pharmaradar360.com/article/fosun-pharma-plots-global-push-beyond-oncology-fueled-by-multi-asset-alzheimer-s-912ab5644687f588Pharma Surgeen2026-06-25T23:00:00.000ZFosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategyhttps://www.pharmaradar360.com/article/bio-notebook-more-us-fda-wordplay-big-pharma-helps-entrances-biotech-m-a-offers-cfb8a7e6b64fa1d3Pharma Surgeen2026-06-25T22:10:56.000ZBIO Notebook: More US FDA Wordplay, Big Pharma Helps Entrances, Biotech M&A Offers Exitshttps://www.pharmaradar360.com/article/bio-notebook-big-pharmas-help-with-entrances-biotech-m-a-offers-exits-e337d796d0769c4cPharma Surgeen2026-06-25T20:48:34.000ZBIO Notebook: Big Pharmas Help With Entrances; Biotech M&A Offers Exitshttps://www.pharmaradar360.com/article/scientists-measure-hidden-quantum-forces-that-could-power-a-new-generation-of-ph-064530258cc8de68Pharma Surgeen2026-06-25T20:20:10.000ZScientists measure hidden quantum forces that could power a new generation of pharmaceutical drugshttps://www.pharmaradar360.com/article/fda-clears-trodelvy-for-first-line-metastatic-triple-negative-breast-cancer-phar-8d7096302d877668Pharma Surgeen2026-06-25T19:03:16.000ZFDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer | PharmExechttps://www.pharmaradar360.com/article/bio-2026-fda-leadership-confront-workforce-losses-china-competition-in-drug-deve-e6715ab3f4d88357Pharma Surgeen2026-06-25T19:00:08.000ZBIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Developmenthttps://www.pharmaradar360.com/article/patient-perceptions-on-the-use-of-ai-in-creating-clinical-research-documents-sur-ef3ac9fbae58b2dePharma Surgeen2026-06-25T18:46:56.000ZPatient Perceptions on the Use of AI in Creating Clinical Research Documents: Survey Studyhttps://www.pharmaradar360.com/article/nipah-virus-disease-india-4ba4a82cc627e48dPharma Surgeen2026-06-25T18:00:00.000ZNipah virus disease - Indiahttps://www.pharmaradar360.com/article/atea-completes-enrollment-in-phase-3-hepatitis-c-trial-988b6fba4c56b860Pharma Surgeen2026-06-25T17:31:50.000ZAtea completes enrollment in phase 3 hepatitis C trialhttps://www.pharmaradar360.com/article/pinnacle-biologics-receives-untitled-letter-from-fda-for-photofrin-a5b982ab392cb95ePharma Surgeen2026-06-25T17:02:20.000ZPinnacle Biologics receives Untitled Letter from FDA for Photofrinhttps://www.pharmaradar360.com/article/fda-says-infant-formula-is-safe-critics-say-agency-left-out-key-information-c8255243ce39189fPharma Surgeen2026-06-25T16:35:04.000ZFDA says infant formula is safe. Critics say agency left out key information.https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-06-25T16:23:37.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/drug-to-prevent-organ-rejection-after-kidney-transplant-tops-standard-treatment-4add60b421db13b6Pharma Surgeen2026-06-25T16:11:35.000ZDrug to prevent organ rejection after kidney transplant tops standard treatment in trialhttps://www.pharmaradar360.com/article/fda-will-reportedly-conclude-abortion-pill-safety-review-by-september-343203b30dba9d6dPharma Surgeen2026-06-25T16:06:00.000ZFDA Will Reportedly Conclude Abortion Pill Safety Review by Septemberhttps://www.pharmaradar360.com/article/senate-unanimously-passes-boscola-backed-legislation-to-modernize-pharmaceutical-66ce988cc92e19cePharma Surgeen2026-06-25T15:41:09.000ZSenate Unanimously Passes Boscola-Backed Legislation to Modernize Pharmaceutical Licensinghttps://www.pharmaradar360.com/article/therapeutics-stocks-q1-teardown-biomarin-pharmaceutical-nasdaq-bmrn-vs-the-rest-56344bfd686cf92dPharma Surgeen2026-06-25T15:37:50.000ZTherapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Resthttps://www.pharmaradar360.com/article/tianjin-development-says-lisheng-pharmaceutical-subscribes-to-investment-product-5908f523f0d969d3Pharma Surgeen2026-06-25T15:33:51.000ZTianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Millionhttps://www.pharmaradar360.com/article/biotech-etf-index-surges-10-after-rebalance-1edcbf3595d1bd45Pharma Surgeen2026-06-25T15:32:51.000ZBiotech ETF Index Surges 10% After Rebalancehttps://www.pharmaradar360.com/article/krystal-biotech-stock-hits-all-time-high-at-357-65-usd-4abb039116198537Pharma Surgeen2026-06-25T15:31:18.000ZKrystal Biotech stock hits all-time high at 357.65 USDhttps://www.pharmaradar360.com/article/2546-a-cluster-randomised-controlled-trial-of-air-filtration-to-prevent-symptoma-5984674e16dbc3d5Pharma Surgeen2026-06-25T15:19:35.000Z2546: A cluster randomised controlled trial of Air Filtration to prevent symptomatic winter Respiratory Infections (including COVID-19) in care homes (AFRI-c)https://www.pharmaradar360.com/article/scoop-members-of-congress-told-abortion-pill-safety-review-possible-by-september-4e04bb31595eb57fPharma Surgeen2026-06-25T15:11:08.000ZSCOOP: Members of Congress Told Abortion Pill Safety Review Possible by Septemberhttps://www.pharmaradar360.com/article/3-fragen-an-unser-neues-boardmitglied-michele-ravara-general-manager-bei-abbvie-df008236250ce191Pharma Surgeen2026-06-25T15:10:21.000Z3 Fragen an unser neues Boardmitglied: Michele Ravara, General Manager bei AbbVie Switzerlandhttps://www.pharmaradar360.com/article/geodis-tests-sustainable-paper-thermal-covers-for-pharmaceutical-airfreight-3801ee1b6af6c9bdPharma Surgeen2026-06-25T15:09:54.000ZGEODIS tests sustainable paper thermal covers for pharmaceutical airfreighthttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-may-2026-b766133bf277f757Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: workforce management information May 2026https://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-january-to-marc-2fa50abc78b19ba4Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: senior officials’ business expenses, hospitality and meetings, January to March 2026https://www.pharmaradar360.com/article/dhsc-ministerial-travel-and-meetings-january-to-march-2026-39ee0c30f2ed7e92Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: ministerial travel and meetings, January to March 2026https://www.pharmaradar360.com/article/dhsc-ministerial-gifts-hospitality-overseas-travel-and-meetings-2332d5d2f3822f2ePharma Surgeen2026-06-25T15:00:08.000ZDHSC: ministerial gifts, hospitality, overseas travel and meetingshttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: workforce management informationhttps://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-a328912eb87631b3Pharma Surgeen2026-06-25T15:00:08.000ZDHSC: senior officials’ business expenses, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-52d34624ad3609c5Pharma Surgeen2026-06-25T15:00:05.000ZDHSC: special advisers' gifts, hospitality and meetingshttps://www.pharmaradar360.com/article/dhsc-special-advisers-gifts-hospitality-and-meetings-january-to-march-2026-f054ee78b3c87d08Pharma Surgeen2026-06-25T15:00:04.000ZDHSC: special advisers' gifts, hospitality and meetings, January to March 2026https://www.pharmaradar360.com/article/natera-s-prospera-test-selected-for-eledon-kidney-transplant-trial-4e00ca424839ec51Pharma Surgeen2026-06-25T14:55:01.000ZNatera’s Prospera test selected for Eledon kidney transplant trialhttps://www.pharmaradar360.com/article/overwhelmingly-a-positive-development-fda-finally-stops-blocking-safe-effective-ca5e9a64365c276aPharma Surgeen2026-06-25T14:46:57.000Z"Overwhelmingly a Positive Development": FDA Finally Stops Blocking Safe, Effective Bemotrizinol Sunscreenshttps://www.pharmaradar360.com/article/contact-the-department-of-health-and-social-care-dhsc-e9faf95887d9a23dPharma Surgeen2026-06-25T14:41:34.000ZContact the Department of Health and Social Care (DHSC)https://www.pharmaradar360.com/article/complaints-procedure-77a8386b7ea0797aPharma Surgeen2026-06-25T14:40:46.000ZComplaints procedurehttps://www.pharmaradar360.com/article/fda-side-effects-update-migraine-drug-constipation-risk-boxed-warning-update-for-d708b4c158502e4aPharma Surgeen2026-06-25T14:32:47.000ZFDA SIDE EFFECTS UPDATE: Migraine Drug Constipation Risk, Boxed Warning Update for Methotrexatehttps://www.pharmaradar360.com/article/health-protection-report-volume-20-2026-f9e0b8a49f9df3c3Pharma Surgeen2026-06-25T14:30:00.000ZHealth Protection Report volume 20 (2026)https://www.pharmaradar360.com/article/the-china-debate-gets-louder-in-washington-09b5ff424f78e3e1Pharma Surgeen2026-06-25T14:25:18.000ZThe China debate gets louder in Washingtonhttps://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60Pharma Surgeen2026-06-25T14:00:00.000ZMeningococcal disease: laboratory-confirmed cases in England 2025 to 2026https://www.pharmaradar360.com/article/menb-vaccine-bexsero-offer-autumn-2026-pgd-template-304b5c86eabf3910Pharma Surgeen2026-06-25T14:00:00.000ZMenB vaccine (Bexsero®) offer Autumn 2026: PGD templatehttps://www.pharmaradar360.com/article/gastrointestinal-infections-and-outbreak-statistics-for-england-05961f6c3dda1ec2Pharma Surgeen2026-06-25T14:00:00.000ZGastrointestinal infections and outbreak statistics for Englandhttps://www.pharmaradar360.com/article/immunisation-patient-group-direction-pgd-templates-1af7ede7c1c283c6Pharma Surgeen2026-06-25T14:00:00.000ZImmunisation patient group direction (PGD) templateshttps://www.pharmaradar360.com/article/united-therapeutics-uthr-is-more-than-a-single-drug-biotech-because-cash-flow-fu-9bdab9637e0b2adfPharma Surgeen2026-06-25T13:49:03.000ZUnited Therapeutics (UTHR) Is More Than a Single-Drug Biotech Because Cash Flow Funds a Broader Transplant Platformhttps://www.pharmaradar360.com/article/natera-and-eledon-announce-strategic-partnership-for-prosperatm-monitoring-in-pl-596d13a4b7c4c42dPharma Surgeen2026-06-25T13:44:57.000ZNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trialhttps://www.pharmaradar360.com/article/price-to-book-forward-of-krystal-biotech-inc-swb-4kb-62c3e1a2b4c5165bPharma Surgeen2026-06-25T13:25:23.000ZPrice to book forward of Krystal Biotech, Inc. – SWB:4KBhttps://www.pharmaradar360.com/article/dolcas-biotech-ceo-highlights-morikol-marine-collagen-science-and-delivery-forma-122452e97ce98dfcPharma Surgeen2026-06-25T13:22:21.000ZDolCas Biotech: CEO highlights Morikol marine collagen science and delivery format R&Dhttps://www.pharmaradar360.com/article/ladder17-podcast-how-exozymes-is-scaling-as-a-public-company-200173f56ee9d291Pharma Surgeen2026-06-25T13:09:02.000ZLadder17 podcast: How eXoZymes is Scaling as a Public Companyhttps://www.pharmaradar360.com/article/u-s-trade-probe-puts-german-drug-prices-under-the-microscope-as-health-innovatio-85899243976a2166Pharma Surgeen2026-06-25T13:05:22.000ZU.S. Trade Probe Puts German Drug Prices Under the Microscope as Health Innovations Advancehttps://www.pharmaradar360.com/article/israeli-founded-ai-biotech-immunai-launches-drug-discovery-collaboration-with-bo-397be0327eaf5310Pharma Surgeen2026-06-25T13:01:05.000ZIsraeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheimhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2025-to-2026-695ba9f5e6b7fd05Pharma Surgeen2026-06-25T13:00:01.000ZWeekly all-cause mortality surveillance: 2025 to 2026https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-06-25T13:00:01.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-06-25T13:00:01.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-06-25T13:00:01.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-06-25T13:00:01.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-06-25T13:00:01.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-06-25T13:00:01.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/is-upstream-bio-inc-upb-a-rising-biotech-opportunity-after-new-analyst-coverage-e6ba253937cf1877Pharma Surgeen2026-06-25T12:42:44.000ZIs Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?https://www.pharmaradar360.com/article/abl-bio-targets-december-phase-3-for-abl111-pursues-record-korea-deal-chosunbiz-f9b9344ffd5d70bePharma Surgeen2026-06-25T12:42:00.000ZAbl Bio targets December phase 3 for ABL111, pursues record Korea deal - CHOSUNBIZhttps://www.pharmaradar360.com/article/legend-biotech-corporation-legn-price-target-raised-to-49-on-lb5006-clinical-pro-cdab0ca54bc1e6ddPharma Surgeen2026-06-25T12:40:48.000ZLegend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progresshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-pharmala-biotech-holdings-inc-otc-mdxxf-385b21e18c534106Pharma Surgeen2026-06-25T12:25:57.000ZPrice to earnings forward of PharmAla Biotech Holdings Inc. – OTC:MDXXFhttps://www.pharmaradar360.com/article/fda-drops-blood-pressure-device-enforcement-against-whoop-41a3d1cd09ca8e10Pharma Surgeen2026-06-25T12:20:00.000ZFDA drops blood pressure device enforcement against Whoophttps://www.pharmaradar360.com/article/3-under-the-radar-biotech-takeover-targets-for-the-next-pharma-buying-spree-4a41de854878b86aPharma Surgeen2026-06-25T12:15:12.000Z3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spreehttps://www.pharmaradar360.com/article/analysing-key-trends-in-china-s-patent-linkage-system-and-their-impact-on-pharma-ec6c5c4d79588af4Pharma Surgeen2026-06-25T12:13:52.000ZAnalysing key trends in China’s patent linkage system and their impact on pharmaceutical patent strategieshttps://www.pharmaradar360.com/article/pharma-pulse-ups-s-cold-chain-buildout-and-abbvie-s-10-9b-immunology-bet-04d3b5b555ff8fa3Pharma Surgeen2026-06-25T12:12:44.000ZPharma Pulse: UPS's Cold Chain Buildout and AbbVie's $10.9B Immunology Bethttps://www.pharmaradar360.com/article/usc-surgeon-david-armstrong-to-lead-nu-3-diabetic-foot-ulcer-trial-94988d2b75b961dcPharma Surgeen2026-06-25T12:02:00.000ZUSC surgeon David Armstrong to lead Nu-3 diabetic foot ulcer trialhttps://www.pharmaradar360.com/article/protecting-patients-ensuring-safe-quality-and-effective-health-products-c170afbc043ac82fPharma Surgeen2026-06-25T12:01:09.000ZProtecting Patients: Ensuring Safe, Quality and Effective Health Productshttps://www.pharmaradar360.com/article/spiriva-capsules-out-of-specification-uniformity-of-delivered-dose-5171bfd828e0fd6bPharma Surgeen2026-06-25T12:00:00.000ZSpiriva Capsules ; Out-of-specification (uniformity of delivered dose)https://www.pharmaradar360.com/article/cordis-project-european-partnership-one-health-antimicrobial-resistance-5a7561924f5a3178Pharma Surgeen2026-06-25T11:53:44.000ZCORDIS project: European Partnership One Health AntiMicrobial Resistancehttps://www.pharmaradar360.com/article/cordis-project-accelerating-a-paediatric-formulation-of-ivermectin-for-the-contr-cc090bc3d86d3f7bPharma Surgeen2026-06-25T11:53:03.000ZCORDIS project: Accelerating a paediatric formulation of ivermectin for the control of Neglected Tropical Diseaseshttps://www.pharmaradar360.com/article/03592716625a124aPharma Surgeen2026-06-25T11:52:38.000ZΠΙΛΟΤΙΚΟ ΠΡΟΓΡΑΜΜΑ ΗΛΕΚΤΡΟΝΙΚΗΣ ΕΚΔΟΣΗΣ ΦΥΛΛΟΥ ΟΔΗΓΙΩΝ ΧΡΗΣΗΣ, ΦΑΡΜΑΚΩΝ ΑΝΘΡΩΠΙΝΗΣ ΧΡΗΣΗΣhttps://www.pharmaradar360.com/article/cordis-project-early-detection-and-management-of-skin-related-neglected-tropical-019f6a5bf7b5acb2Pharma Surgeen2026-06-25T11:49:34.000ZCORDIS project: Early detection and management of SKIN-related negleCted tropical diseases using Artificial Intelligence in sub-saharan afRica (SkincAIr)https://www.pharmaradar360.com/article/cordis-project-toxicity-of-dolutegravir-and-evaluation-of-doravirine-for-alterna-4d4cacba202fd548Pharma Surgeen2026-06-25T11:49:30.000ZCORDIS project: Toxicity of dolutegravir and evaluation of doravirine for alternative 1st line antiretroviral treatment in people living with HIVhttps://www.pharmaradar360.com/article/cordis-project-enhanced-preventive-antiparasitic-treatment-for-better-health-of-11ffd64337c415efPharma Surgeen2026-06-25T11:49:30.000ZCORDIS project: Enhanced preventive antiparasitic treatment for better health of African pregnants and their babieshttps://www.pharmaradar360.com/article/5-small-drug-stocks-to-invest-in-amid-a-biotech-comeback-f744fd2e24521b11Pharma Surgeen2026-06-25T11:48:02.000Z5 Small Drug Stocks to Invest in Amid a Biotech Comebackhttps://www.pharmaradar360.com/article/viking-therapeutics-starts-human-clinical-trials-for-new-obesity-drug-following-af2d1f3e1d7b4d8cPharma Surgeen2026-06-25T11:46:18.000ZViking Therapeutics Starts Human Clinical Trials For New Obesity Drug Following Federal Regulatory Clearancehttps://www.pharmaradar360.com/article/botulism-diagnosis-data-and-analysis-943c3264edccc127Pharma Surgeen2026-06-25T11:38:34.000ZBotulism: diagnosis, data and analysishttps://www.pharmaradar360.com/article/vivani-medical-receives-regulatory-approval-for-the-initiation-of-slim-1-a-phase-8a04eac5ac69378cPharma Surgeen2026-06-25T11:30:00.000ZVivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Managementhttps://www.pharmaradar360.com/article/fda-has-the-wrong-mission-that-s-why-it-fails-3bc4bccd0a8b6d4aPharma Surgeen2026-06-25T11:27:31.000ZFDA Has the Wrong Mission. That’s Why It Fails.https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-krystal-biotech-inc-nasdaq-krys-867a8b0412d7ec27Pharma Surgeen2026-06-25T11:07:34.000ZEnterprise value to EBIT forward of Krystal Biotech, Inc. – NASDAQ:KRYShttps://www.pharmaradar360.com/article/as-compounding-pharmacies-expand-patients-are-left-in-the-dark-about-drug-risks-994a866a7284bd85Pharma Surgeen2026-06-25T11:07:06.000ZAs compounding pharmacies expand, patients are left in the dark about drug riskshttps://www.pharmaradar360.com/article/q-a-the-reason-behind-lilly-s-pennsylvania-facility-aa8353b86ca117ebPharma Surgeen2026-06-25T11:03:18.000ZQ&A: The Reason Behind Lilly's Pennsylvania Facilityhttps://www.pharmaradar360.com/article/tiziana-announces-last-patient-successfully-dosed-in-its-phase-2-inform-ms-trial-776d6941dd04ed0aPharma Surgeen2026-06-25T11:00:00.000ZTiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trialhttps://www.pharmaradar360.com/article/atea-pharmaceuticals-completes-patient-enrollment-in-phase-d0121b8b6a34fb87Pharma Surgeen2026-06-25T11:00:00.000ZAtea Pharmaceuticals Completes Patient Enrollment in Phasehttps://www.pharmaradar360.com/article/eledon-trial-will-use-natera-s-prospera-test-to-track-kidney-rejection-0c1cf7019f6f19edPharma Surgeen2026-06-25T11:00:00.000ZEledon trial will use Natera’s Prospera test to track kidney rejectionhttps://www.pharmaradar360.com/article/atea-enrolls-880-plus-patients-in-global-hepatitis-c-trial-71a02ca3a6199edbPharma Surgeen2026-06-25T11:00:00.000ZAtea enrolls 880-plus patients in global hepatitis C trialhttps://www.pharmaradar360.com/article/natera-and-eledon-announce-strategic-partnership-for-prosperatm-monitoring-in-pl-8c0a1e393608c3b4Pharma Surgeen2026-06-25T11:00:00.000ZNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trialhttps://www.pharmaradar360.com/article/ionis-bags-30m-from-recordati-for-ex-us-rights-to-near-approval-rare-disease-pro-42847fcec46f2aa0Pharma Surgeen2026-06-25T10:59:22.000ZIonis bags $30M from Recordati for ex-US rights to near-approval rare disease prospecthttps://www.pharmaradar360.com/article/implementing-reporter-assay-based-mat-for-rapid-pyrogen-detection-8b81b2d0df440f0fPharma Surgeen2026-06-25T10:54:01.000ZImplementing reporter assay-based MAT for rapid pyrogen detectionhttps://www.pharmaradar360.com/article/adc-therapeutics-cuts-jobs-as-zynlonta-fda-talks-loom-0da62cecfc556d61Pharma Surgeen2026-06-25T10:46:37.000ZADC Therapeutics cuts jobs as Zynlonta FDA talks loomhttps://www.pharmaradar360.com/article/fda-approves-keytruda-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahy-9e3103fd262e9ca3Pharma Surgeen2026-06-25T10:45:00.000ZFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)https://www.pharmaradar360.com/article/what-medicare-part-d-patients-need-to-know-about-accessing-foundayo-orforglipron-495b5bc0715962aePharma Surgeen2026-06-25T10:45:00.000ZWhat Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight managementhttps://www.pharmaradar360.com/article/germany-s-merck-boosts-life-sciences-business-with-11-billion-bio-techne-deal-439433ef70682802Pharma Surgeen2026-06-25T10:39:48.000ZGermany's Merck boosts life sciences business with $11 billion Bio-Techne dealhttps://www.pharmaradar360.com/article/julie-kim-takes-top-job-at-takeda-after-weber-retirement-b4180ad723a22828Pharma Surgeen2026-06-25T10:36:34.000ZJulie Kim takes top job at Takeda after Weber retirementhttps://www.pharmaradar360.com/article/hotels-restaurants-must-provide-free-water-says-maharashtra-fda-issues-comprehen-66f7c6cc089f5948Pharma Surgeen2026-06-25T10:30:00.000ZHotels, restaurants must provide free water, says Maharashtra FDA; issues comprehensive order on food safetyhttps://www.pharmaradar360.com/article/the-realities-of-pharmaceutical-onshoring-a-cdmo-perspective-97826e8a57c406d1Pharma Surgeen2026-06-25T10:29:48.000ZThe realities of pharmaceutical onshoring: a CDMO perspectivehttps://www.pharmaradar360.com/article/helus-pharma-help-prices-us-50m-share-sale-to-fund-phase-3-mdd-trial-d8ea228dd4ec6ea8Pharma Surgeen2026-06-25T10:28:24.000ZHelus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trialhttps://www.pharmaradar360.com/article/highs-and-lows-u-s-drug-prices-in-2025-30c6b0553826f540Pharma Surgeen2026-06-25T10:01:51.000ZHighs and Lows: U.S. Drug Prices in 2025https://www.pharmaradar360.com/article/remix-to-enter-nasdaq-through-passage-bio-reverse-merger-8376b2eb62b20bcbPharma Surgeen2026-06-25T10:01:41.000ZRemix to enter Nasdaq through Passage Bio reverse mergerhttps://www.pharmaradar360.com/article/bio-usa-abl-bio-ceo-sanghoon-lee-phase-3-gastric-cancer-drug-trial-to-begin-this-2d70dc937e4065b3Pharma Surgeen2026-06-25T09:49:46.000Z[BIO USA] ABL Bio CEO Sanghoon Lee: "Phase 3 Gastric Cancer Drug Trial to Begin This Year"https://www.pharmaradar360.com/article/yomiuri-takeda-pharmaceutical-s-weber-says-company-in-good-position-for-the-futu-047136d64315ff33Pharma Surgeen2026-06-25T09:48:00.000ZYomiuri: Takeda Pharmaceutical's Weber Says Company in 'Good Position for the Future' As He Steps Downhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-rtw-biotech-opportunities-ltd-usd-fwb-0bm-c2077f82544a2b0dPharma Surgeen2026-06-25T09:46:44.000ZPrice to sales forward of RTW Biotech Opportunities Ltd USD – FWB:0BMhttps://www.pharmaradar360.com/article/price-to-book-forward-of-biomarin-pharmaceutical-inc-gettex-bm8-3ee4a9848c61c8c4Pharma Surgeen2026-06-25T09:45:48.000ZPrice to book forward of BioMarin Pharmaceutical Inc. – GETTEX:BM8https://www.pharmaradar360.com/article/price-to-book-forward-of-feng-chi-biotech-corp-tpex-6744-77fa59a7cbfb2d98Pharma Surgeen2026-06-25T09:45:23.000ZPrice to book forward of Feng Chi Biotech Corp. – TPEX:6744https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-krystal-biotech-inc-nasdaq-krys-54c6a4113e936644Pharma Surgeen2026-06-25T09:34:32.000ZEnterprise value to revenue forward of Krystal Biotech, Inc. – NASDAQ:KRYShttps://www.pharmaradar360.com/article/pharmaceutical-regulatory-update-2026-eu-uk-fda-global-changes-explained-729ffc5c9f68e41cPharma Surgeen2026-06-25T09:34:02.000ZPharmaceutical regulatory update 2026: EU, UK, FDA & global changes explainedhttps://www.pharmaradar360.com/article/the-biotech-founder-asking-why-good-science-gets-stuck-c66cdcc4fc783570Pharma Surgeen2026-06-25T09:29:58.000ZThe biotech founder asking why good science gets stuckhttps://www.pharmaradar360.com/article/guidance-mhra-innovation-office-guidance-and-support-d55aaa5713ffae60Pharma Surgeen2026-06-25T09:16:18.000ZGuidance: MHRA Innovation Office: guidance and supporthttps://www.pharmaradar360.com/article/tracking-cathie-wood-major-ai-biotech-discovery-bet-on-recursion-heavy-reduction-513492f11d900cbePharma Surgeen2026-06-25T09:03:26.000ZTracking Cathie Wood: Major AI Biotech Discovery Bet on Recursion, Heavy Reduction in Absci Holdingshttps://www.pharmaradar360.com/article/bio-2026-how-nih-cuts-have-threatened-us-competitiveness-against-china-b4bc17e6dfc4e7caPharma Surgeen2026-06-25T09:03:05.000ZBIO 2026: How NIH cuts have threatened US competitiveness against Chinahttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-stake-increased-by-sg-americas-securitie-4fddb2b2b48d6a0bPharma Surgeen2026-06-25T08:55:10.000ZTeva Pharmaceutical Industries Ltd. $TEVA Stake Increased by SG Americas Securities LLChttps://www.pharmaradar360.com/article/bio-2026-indiana-biopharma-investment-and-the-lilly-effect-2c0308532361277ePharma Surgeen2026-06-25T08:53:04.000ZBIO 2026: Indiana, biopharma investment and the Lilly effecthttps://www.pharmaradar360.com/article/abl-bio-is-launching-phase-3-global-clinical-trials-of-its-new-gastric-cancer-dr-0a6fe21423b25f84Pharma Surgeen2026-06-25T08:50:09.000ZABL Bio is launching phase 3 global clinical trials of its new gastric cancer drug "ABL111" within t..https://www.pharmaradar360.com/article/vaccine-schedule-change-helps-protect-babies-earlier-against-meningitis-b-9d70be5a1c71dee4Pharma Surgeen2026-06-25T08:50:00.000ZVaccine schedule change helps protect babies earlier against meningitis Bhttps://www.pharmaradar360.com/article/tvtx-lgnd-stocks-in-spotlight-ahead-of-monday-s-fda-call-on-kidney-drug-filspari-fa6238499aaae213Pharma Surgeen2026-06-25T08:49:49.000ZTVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filsparihttps://www.pharmaradar360.com/article/biosecure-didn-t-stop-china-s-rise-in-biotech-some-lawmakers-want-to-do-more-f301323cecb6df92Pharma Surgeen2026-06-25T08:30:49.000ZBiosecure didn’t stop China’s rise in biotech. Some lawmakers want to do morehttps://www.pharmaradar360.com/article/hsbc-holdings-plc-lowers-holdings-in-teva-pharmaceutical-industries-ltd-teva-7c8039a60abac925Pharma Surgeen2026-06-25T08:30:14.000ZHsbc Holdings PLC Lowers Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-06-25T08:30:11.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-06-25T08:30:11.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-06-25T08:30:11.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-06-25T08:30:11.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/tetanus-in-england-annual-reports-55f6cea4b8ae62acPharma Surgeen2026-06-25T08:30:06.000ZTetanus in England: annual reportshttps://www.pharmaradar360.com/article/pertussis-laboratory-confirmed-cases-reported-in-england-2025-aad4dec619bb9eebPharma Surgeen2026-06-25T08:30:06.000ZPertussis: laboratory confirmed cases reported in England 2025https://www.pharmaradar360.com/article/fungaemia-including-candidaemia-annual-data-from-voluntary-surveillance-edab4d6534b55584Pharma Surgeen2026-06-25T08:30:05.000ZFungaemia (including candidaemia): annual data from voluntary surveillancehttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9Pharma Surgeen2026-06-25T08:30:04.000ZCover of vaccination evaluated rapidly (COVER) programme 2025 to 2026: quarterly datahttps://www.pharmaradar360.com/article/epidemiology-of-covid-19-in-england-42b3d6340228a3a1Pharma Surgeen2026-06-25T08:30:01.000ZEpidemiology of COVID-19 in Englandhttps://www.pharmaradar360.com/article/childhood-vaccination-coverage-provisional-monthly-data-for-england-096cd364d32970b8Pharma Surgeen2026-06-25T08:30:00.000ZChildhood vaccination coverage: provisional monthly data for Englandhttps://www.pharmaradar360.com/article/record-hk-delegation-showcases-life-sciences-edge-in-san-diego-d2fe7fddc7b7a210Pharma Surgeen2026-06-25T08:12:28.000ZRecord HK delegation showcases life sciences edge in San Diegohttps://www.pharmaradar360.com/article/barometre-360-de-l-attractivite-de-la-france-pour-l-industrie-pharmaceutique-edi-19ff4524e0f1f3cbPharma Surgeen2026-06-25T08:12:20.000ZBaromètre 360° de l’attractivité de la France pour l’industrie pharmaceutique - Edition 2026 : Accès aux traitements, progrès thérapeutique, attractivité de la France : reprendre l’avantage ou décrocher ?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-biomarin-pharmaceutical-inc-nasdaq-bmrn-07de7e9244ed0d80Pharma Surgeen2026-06-25T08:07:27.000ZEnterprise value to EBITDA forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRNhttps://www.pharmaradar360.com/article/bio-usa-2026-abl-bio-bets-on-neok-bio-to-create-us-style-value-through-later-sta-916cd58628f8df6ePharma Surgeen2026-06-25T08:00:00.000Z[BIO USA 2026] ABL Bio bets on Neok Bio to create US-Style value through later-stage clinical developmenthttps://www.pharmaradar360.com/article/can-restaurants-charge-you-for-drinking-water-maharashtra-fda-s-new-order-says-71de6bd0b9d2b43bPharma Surgeen2026-06-25T07:58:59.000ZCan Restaurants Charge You For Drinking Water? Maharashtra FDA’s New Order Says…https://www.pharmaradar360.com/article/ipsen-recognized-at-lten-excellence-awards-2026-for-transforming-field-leadershi-1629ad33c263ee6fPharma Surgeen2026-06-25T07:57:06.000ZIpsen recognized at LTEN Excellence Awards 2026 for transforming field leadership through coachinghttps://www.pharmaradar360.com/article/are-you-working-with-cell-therapy-and-planning-a-clinical-trial-fa8ac360a3c2413fPharma Surgeen2026-06-25T07:52:00.000ZAre you working with cell therapy and planning a clinical trial?https://www.pharmaradar360.com/article/east-asia-s-biotech-autonomy-push-is-already-stunting-innovation-808f966407a0c507Pharma Surgeen2026-06-25T07:37:11.000ZEast Asia’s biotech autonomy push is already stunting innovationhttps://www.pharmaradar360.com/article/zepzelca-8340fbf8b145e16dPharma Surgeen2026-06-25T07:12:30.000ZZepzelcahttps://www.pharmaradar360.com/article/jazz-pharmaceuticals-zepzelca-misses-primary-endpoint-in-phase-3-lung-cancer-tri-48295a4697676f4fPharma Surgeen2026-06-25T07:02:45.000ZJazz Pharmaceuticals Zepzelca Misses Primary Endpoint in Phase 3 Lung Cancer Trialhttps://www.pharmaradar360.com/article/recordati-announces-license-agreement-with-ionis-pharmaceuticals-for-zilganersen-7e85659ea7fd2290Pharma Surgeen2026-06-25T06:59:07.000ZRECORDATI ANNOUNCES LICENSE AGREEMENT WITH IONIS PHARMACEUTICALS FOR ZILGANERSEN FOR THE TREATMENT OF ALEXANDER DISEASE IN ALL COUNTRIES OUTSIDE THE U.S.https://www.pharmaradar360.com/article/innovative-molecules-starts-phase-2a-trial-of-adibelivir-for-genital-herpes-047bbdcddb80d36dPharma Surgeen2026-06-25T06:58:04.000ZInnovative Molecules Starts Phase 2a Trial of Adibelivir for Genital Herpeshttps://www.pharmaradar360.com/article/phathom-completes-enrollment-in-phase-2-vonoprazan-eoe-trial-ahead-of-schedule-3484446d89200c5fPharma Surgeen2026-06-25T06:53:04.000ZPhathom Completes Enrollment in Phase 2 Vonoprazan EoE Trial Ahead of Schedulehttps://www.pharmaradar360.com/article/fda-backs-entera-bio-s-phase-3-plan-for-oral-eb613-osteoporosis-drug-e2e36f34828d0b7ePharma Surgeen2026-06-25T06:53:04.000ZFDA Backs Entera Bio’s Phase 3 Plan for Oral EB613 Osteoporosis Drughttps://www.pharmaradar360.com/article/maharashtra-fda-bans-serving-food-in-newspapers-issues-statewide-food-safety-ord-b2a326d0eb8af15dPharma Surgeen2026-06-25T06:48:00.000ZMaharashtra FDA bans serving food in newspapers, issues statewide food safety orderhttps://www.pharmaradar360.com/article/eli-lilly-signs-new-partnership-deal-with-china-s-abbisko-84d661d5953aa368Pharma Surgeen2026-06-25T06:39:59.000ZEli Lilly signs new partnership deal with China's Abbiskohttps://www.pharmaradar360.com/article/matters-concerning-controlling-shareholders-etc-466420396ec1213cPharma Surgeen2026-06-25T06:30:00.000ZMatters Concerning Controlling Shareholders, Etc.https://www.pharmaradar360.com/article/atrasentan-06d83d835d0cce4bPharma Surgeen2026-06-25T06:27:51.000ZAtrasentan